CN112587658A - 癌症的靶向免疫治疗 - Google Patents
癌症的靶向免疫治疗 Download PDFInfo
- Publication number
- CN112587658A CN112587658A CN202011353425.2A CN202011353425A CN112587658A CN 112587658 A CN112587658 A CN 112587658A CN 202011353425 A CN202011353425 A CN 202011353425A CN 112587658 A CN112587658 A CN 112587658A
- Authority
- CN
- China
- Prior art keywords
- cancer
- antibody
- molecule
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 128
- 201000011510 cancer Diseases 0.000 title claims description 58
- 238000009169 immunotherapy Methods 0.000 title description 9
- 230000008685 targeting Effects 0.000 claims abstract description 30
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 15
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 15
- 230000002584 immunomodulator Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 91
- 102000002689 Toll-like receptor Human genes 0.000 claims description 28
- 108020000411 Toll-like receptor Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000003446 ligand Substances 0.000 claims description 24
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- -1 Avintegrin Proteins 0.000 claims description 21
- 230000002159 abnormal effect Effects 0.000 claims description 21
- 229960000575 trastuzumab Drugs 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 125000005647 linker group Chemical group 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 230000002062 proliferating effect Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
- 210000000481 breast Anatomy 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 11
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 11
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 11
- 229960004397 cyclophosphamide Drugs 0.000 claims description 11
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 10
- 229960002949 fluorouracil Drugs 0.000 claims description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 7
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 7
- 102000002227 Interferon Type I Human genes 0.000 claims description 7
- 108010014726 Interferon Type I Proteins 0.000 claims description 7
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 7
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 7
- 229960004679 doxorubicin Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 230000009545 invasion Effects 0.000 claims description 7
- 229960004641 rituximab Drugs 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 6
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 6
- 108010069236 Goserelin Proteins 0.000 claims description 6
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 229960001904 epirubicin Drugs 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002751 imiquimod Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229940086322 navelbine Drugs 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 102100025221 CD70 antigen Human genes 0.000 claims description 5
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- 108010092160 Dactinomycin Proteins 0.000 claims description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 5
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 5
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 5
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 5
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 108091008605 VEGF receptors Proteins 0.000 claims description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 5
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 5
- 229960001220 amsacrine Drugs 0.000 claims description 5
- 229960002932 anastrozole Drugs 0.000 claims description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960000640 dactinomycin Drugs 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229960003668 docetaxel Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229930013356 epothilone Natural products 0.000 claims description 5
- 229940082789 erbitux Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- 229960000255 exemestane Drugs 0.000 claims description 5
- 229960002913 goserelin Drugs 0.000 claims description 5
- 229940022353 herceptin Drugs 0.000 claims description 5
- 229960000908 idarubicin Drugs 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 229960003881 letrozole Drugs 0.000 claims description 5
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001156 mitoxantrone Drugs 0.000 claims description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 5
- 229950006344 nocodazole Drugs 0.000 claims description 5
- 229960004622 raloxifene Drugs 0.000 claims description 5
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 5
- 229960001603 tamoxifen Drugs 0.000 claims description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 5
- 229960001278 teniposide Drugs 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 5
- 229960004528 vincristine Drugs 0.000 claims description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 4
- 108010055191 EphA3 Receptor Proteins 0.000 claims description 4
- 108010055334 EphB2 Receptor Proteins 0.000 claims description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 4
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 4
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 4
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 4
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 4
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100035486 Nectin-4 Human genes 0.000 claims description 4
- 101710043865 Nectin-4 Proteins 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 108091007561 SLC44A4 Proteins 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 4
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- MKSPBYRGLCNGRC-OEMOKZHXSA-N (2s)-2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-aminopropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound O=C([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)CC(C)C)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MKSPBYRGLCNGRC-OEMOKZHXSA-N 0.000 claims description 3
- HIKCELHIZSKMGI-LJAQVGFWSA-N (2s)-3-[[4-[[1h-benzimidazol-2-ylmethyl(cyclohexylcarbamoyl)amino]methyl]benzoyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical group C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)NC(=O)C(C=C1)=CC=C1CN(CC=1NC2=CC=CC=C2N=1)C(=O)NC1CCCCC1 HIKCELHIZSKMGI-LJAQVGFWSA-N 0.000 claims description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 3
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 108010051834 CTTHWGFTLC peptide Proteins 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 claims description 3
- 108010016076 Octreotide Proteins 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 3
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- OKYYOKGIPDRZJA-CPSXWDTOSA-N chembl2103792 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 OKYYOKGIPDRZJA-CPSXWDTOSA-N 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 238000000375 direct analysis in real time Methods 0.000 claims description 3
- 238000012063 dual-affinity re-targeting Methods 0.000 claims description 3
- BPSMYQFMCXXNPC-MFCPCZTFSA-N eritoran Chemical compound O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP(O)(O)=O)[C@@H](COC)O1 BPSMYQFMCXXNPC-MFCPCZTFSA-N 0.000 claims description 3
- 229950007107 eritoran Drugs 0.000 claims description 3
- LEEIJTHMHDMWLJ-CQSZACIVSA-N ethyl (6r)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate Chemical compound CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC1=CC=C(F)C=C1Cl LEEIJTHMHDMWLJ-CQSZACIVSA-N 0.000 claims description 3
- 108010021336 lanreotide Proteins 0.000 claims description 3
- 229960002437 lanreotide Drugs 0.000 claims description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 229940087857 lupron Drugs 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 229960002700 octreotide Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 3
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 claims description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229950001741 agatolimod Drugs 0.000 claims description 2
- 201000005389 breast carcinoma in situ Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 125000002228 disulfide group Chemical group 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 2
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 201000011059 lobular neoplasia Diseases 0.000 claims description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 2
- 229960002730 vapreotide Drugs 0.000 claims description 2
- 108700029852 vapreotide Proteins 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 241001435619 Lile Species 0.000 claims 1
- 206010025598 Malignant hydatidiform mole Diseases 0.000 claims 1
- 108091005685 RIG-I-like receptors Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102100038126 Tenascin Human genes 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000005597 hydrazone group Chemical group 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000101 thioether group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 30
- 150000001875 compounds Chemical class 0.000 abstract description 20
- 230000008878 coupling Effects 0.000 abstract description 13
- 238000010168 coupling process Methods 0.000 abstract description 13
- 238000005859 coupling reaction Methods 0.000 abstract description 13
- 230000008105 immune reaction Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 31
- 229940079593 drug Drugs 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 22
- 210000004443 dendritic cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 11
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 11
- 229950010550 resiquimod Drugs 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 8
- 239000000562 conjugate Substances 0.000 description 8
- 239000000611 antibody drug conjugate Substances 0.000 description 7
- 229940049595 antibody-drug conjugate Drugs 0.000 description 7
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 108020005243 folate receptor Proteins 0.000 description 7
- 102000006815 folate receptor Human genes 0.000 description 7
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 229930126263 Maytansine Natural products 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 102000000844 Cell Surface Receptors Human genes 0.000 description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000009175 antibody therapy Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229960001612 trastuzumab emtansine Drugs 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710088083 Glomulin Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 3
- 102000007000 Tenascin Human genes 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229960000455 brentuximab vedotin Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 150000007857 hydrazones Chemical group 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000012064 NLR Proteins Human genes 0.000 description 2
- 108091005686 NOD-like receptors Proteins 0.000 description 2
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 229940124669 imidazoquinoline Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- WCBVQNZTOKJWJS-ACZMJKKPSA-N Ala-Cys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O WCBVQNZTOKJWJS-ACZMJKKPSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- QDGMZAOSMNGBLP-MRFFXTKBSA-N Ala-Trp-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N QDGMZAOSMNGBLP-MRFFXTKBSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- FNXCAFKDGBROCU-STECZYCISA-N Arg-Ile-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FNXCAFKDGBROCU-STECZYCISA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 1
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- KHGPWGKPYHPOIK-QWRGUYRKSA-N Asp-Gly-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KHGPWGKPYHPOIK-QWRGUYRKSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 description 1
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 description 1
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 1
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 1
- BCFXQBXXDSEHRS-FXQIFTODSA-N Cys-Ser-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BCFXQBXXDSEHRS-FXQIFTODSA-N 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- YGLCLCMAYUYZSG-AVGNSLFASA-N Glu-Lys-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 YGLCLCMAYUYZSG-AVGNSLFASA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 1
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- HZWWOGWOBQBETJ-CUJWVEQBSA-N His-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O HZWWOGWOBQBETJ-CUJWVEQBSA-N 0.000 description 1
- ZNTSGDNUITWTRA-WDSOQIARSA-N His-Trp-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O ZNTSGDNUITWTRA-WDSOQIARSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101100203782 Homo sapiens SPG7 gene Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- RMNMUUCYTMLWNA-ZPFDUUQYSA-N Ile-Lys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RMNMUUCYTMLWNA-ZPFDUUQYSA-N 0.000 description 1
- QQFSKBMCAKWHLG-UHFFFAOYSA-N Ile-Phe-Pro-Pro Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(NC(=O)C(N)C(C)CC)CC1=CC=CC=C1 QQFSKBMCAKWHLG-UHFFFAOYSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- HMZPYMSEAALNAE-ULQDDVLXSA-N Lys-Val-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMZPYMSEAALNAE-ULQDDVLXSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100027006 Paraplegin Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 1
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 1
- UGFOSENEZHEQKX-PJODQICGSA-N Trp-Val-Ala Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(O)=O UGFOSENEZHEQKX-PJODQICGSA-N 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 1
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 101150051070 gppA gene Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108010059074 monomethylauristatin F Proteins 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- QGFSVPWZEPKNDV-BRTFOEFASA-N ranp Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)[C@@H](C)CC)C1=CC=CC=C1 QGFSVPWZEPKNDV-BRTFOEFASA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010058119 tryptophyl-glycyl-glycine Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提供了一种针对肿瘤的靶向集团和免疫调节剂的偶联复合物。此种复合物能在肿瘤微环境中激活针对肿瘤的免疫反应,特异性地杀伤肿瘤细胞,从而达到治疗肿瘤的目的。
Description
本申请是申请号为201210248481.9、申请日为2012年7月18日、发明名称为“癌症的靶向免疫治疗”的发明专利申请的分案申请。
发明背景:
治疗性抗体在临床上的应用已有二十多年的时间了,临床应用的抗肿瘤抗体药物现在已有十三种,包括Rituxan(1997),Herceptin(1998),Mylotarg(2000),Campath(2001),Zevalin(2002),Bexxer(2003),Avastin(2004),Erbitux(2004)和Vectibix(2006);Arzerra(2009);Benlysta(2011);Yervoy(2011);Adcetris(2011)。靶点主要集中在EGFR,Her2,CD20和VEGF四个分子上。
单纯的治疗性抗体的肿瘤细胞杀伤机制有三种(Scott AM,Wolchok JD,OldLJ.Antibody therapy of cancer.Nat Rev Cancer.2012Mar 22;12(4):278-87):1)抗体的直接作用即抗体使配体/受体信号的阻断或激动活性、诱导凋亡、呈递药物。抗体的受体激动活性可产生直接肿瘤细胞杀伤作用,比如,有些抗体可结合到肿瘤细胞表面受体上,激活该受体,从而导致细胞凋亡(以线粒体为代表)。抗体也可以通过受体拮抗活性介导肿瘤细胞杀伤,比如,某些抗体可结合到细胞表面受体上,并阻断二聚化、激酶激活和下游信号,从而抑制增殖,促进凋亡。抗体结合到酶上可以导致中和作用、信号阻断和细胞死亡。2)通过免疫介导的细胞杀伤机制包括补体依赖的细胞毒作用(complement-dependentcytotoxicity,CDC),抗体依赖细胞介导的细胞毒作用(antibody-dependent cellularcytotoxicity,ADCC),T细胞功能调控等。免疫介导的肿瘤细胞杀伤可通过以下途径来完成:诱导吞噬作用;补体激活;抗体依赖细胞介导的细胞毒作用;遗传修饰的T细胞通过单链可变片段靶向肿瘤;通过抗体介导抗原交叉递呈给树突状细胞激活T细胞;抑制T细胞抑制性受体,如细胞毒性T淋巴细胞相关抗原4(CTLA4)。其中抗体Fc部分的功能对于通过CDC和ADCC介导的肿瘤细胞杀伤作用尤其重要。3)抗体对肿瘤血管和基质的特异性效应。通过对血管受体拮抗或配体捕获诱导血管和基质细胞消融,包括:基质细胞的抑制作用;向基质细胞传递毒素;向脉管系统传递毒素。(Scott AM,Wolchok JD,Old LJ.Antibody therapy ofcancer.Nat Rev Cancer.2012Mar 22;12(4):278-87.)
单纯治疗性单抗药物的推动了抗癌药物的研究发展,但仍有些问题需要进一步研究解决。例如抗体的免疫原性,长期使用的肿瘤靶点耐受,单纯阻断单一信号传导通路的长期效果等等,总而言之,绝大部分的单纯抗体都较难做到长期的,高效率的抑制和杀伤肿瘤细胞。
1964年《自然》杂志提出了抗体-药物偶联(ADC)技术的新思路,这方面的技术在近年来有了突破性的进展。ADC是一种通过化学连接子(linker)将强毒性药物(Toxin)与抗体共价连接起来。抗体识别癌细胞表面的抗原分子,由于细胞内吞ADC药物的作用将其内吞至胞质内,在胞内特殊环境下,Linker水解后释放的毒素来杀伤细胞。
Seattle Genetics公司开发的这类药物Brentuximab Vedotin(商品名Adcetris)已通过了FDA的上市批准。它是由monomethyl auristatin E(MMAE)这种人工合成的毒性抗癌药和特异性靶向淋巴瘤细胞特异性的CD30分子的抗体偶联而成,提高了杀灭肿瘤细胞的作用。
现在,有数十款这类ADC药物正在开展临床试验,其中Genentech生物技术公司和ImmunoGen公司联合开发的曲妥珠单抗与美登素偶联成的,用于治疗乳腺癌的药物T-DM1已经进入了最后上市前准备。美登素是一种小分子毒素,可与微管蛋白结合,通过非还原的双-马来酰亚胺-丙二醇联合体防止微管形成。而曲妥珠单抗可靶向作用于乳腺癌和胃癌人表皮生长因子受体2(HER2),是被批准用于HER2阳性的癌症的新药,但曲妥珠单抗并非能够促使所有的HER2阳性细胞凋亡。T-DM1结合了选择性地靶向HER2受体的曲妥珠单抗与强效的细胞毒性剂maytansine而杀死肿瘤细胞。即T-DM1抗体与HER2受体结合,引起从偶联物释放的美登素细胞内化,进而杀死肿瘤细胞。T-DM1具有较好的整体疗效和药代动力学特性,并且毒性较低。
传统的小分子化疗药物具有毒性强和药代动力学的优势,但在治疗肿瘤过程中可能结合和影响其他生理靶点产生严重的副作用;抗体-药物偶联就是把具有优异临床疗效的靶向特异性抗体和小分子药物的药代动力学结合起来。抗体药物偶联物结构是具有靶向作用的单克隆抗体与具有特定药理学特性的化合物结合。这种技术的要求是治疗性抗体必须具有靶点结合特异性;必须与一个具有治疗或其他功能作用的分子如细胞毒素偶联,诸多因素影响这类抗体的作用如偶联抗体的细胞内吞功能、偶联稳定性、细胞毒素的释放及杀伤性等。
目前常用的毒素分子主要包括微管蛋白抑制剂Auristatin类似物monomethylauristatin E,monomethyl auristatin F和美登素。monomethyl auristatin E是人工合成的微管聚合物抑制剂,能够抑制微管聚集,干扰肿瘤细胞有丝分裂和凋亡诱导作用(Naumovski L and Junutula JR.Glembatumumab vedotin,a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatinE for the treatment of melanoma and breast cancer.Curr Opin Mol Ther 2003;12(2):248-57.Francisco JA,Cerveny CG et al.cAC10-vcMMAE,an anti-CD30-monomethylauristatin E conjugate with potent and selective antitumor activity.Blood 102(4):1458-65)monomethyl auristatin F是一种抗有丝分裂的Auristatin衍生物,C末端具有带电荷的苯基丙氨酸残基,与未带电荷的MMAE相比,它最小化细胞信号通路的损伤,最小化细胞毒性。在大量CD30细胞株试验中发现,mAb-maleimidocaproyl-缬氨酸-瓜氨酸-p-aminobenzyloxycarbonyl-MMAF(mAb-L1-MMAF)的毒性比单独MMAF强2200倍以上(DoroninaSO et al.,Enhanced activity of monomethylauristatin F through monoclonalantibody delivery:effects of linker technology on efficacy andtoxicity.Bioconjug Chem,2006;17(1):p114-24)。美登素也是一种能与微管蛋白结合小分子毒素,通过非还原的双-马来酰亚胺-丙二醇联合体防止微管形成。
抗体-药物偶联具有直接和间接杀伤癌细胞的作用,这种抗体使配体/受体信号的阻断或激动活性、诱导凋亡同时还可以将负载药物直接或间接(例如药物、毒素、小分子干扰RNA或放射性同位素)呈递或传递给肿瘤细胞。治疗性偶联抗体药物就是利用抗体和偶联药物的双重特性,一是结合功能,与靶分子特异性结合;二是抗体本身肿瘤细胞杀伤的效应功能,三是偶联药物的特定功效。目前的抗体-药物偶联药物是局限在如何直接杀伤肿瘤细胞。但基于这种技术在抗体,链接分子,毒素分子,链接技术等方面的高要求,以及能够带到肿瘤微环境内的毒素分子有限,在实际临床研究方面还存在着一定困难。
本文引用的参考文献不应视为承认是请求保护的本发明的现有技术。
发明概述
本发明涉及一个用于治疗肿瘤的具有靶向细胞功效以及细胞免疫调节功能的免疫治疗分子,此免疫治疗分子是具有靶向集团-链接分子-调节剂结构的偶联复合物。此免疫治疗分子在体内能达到杀伤肿瘤细胞同时更有效的激活肿瘤免疫和的作用。
本发明提供一种靶向免疫治疗分子,其具有如下结构:靶向集团,连接集团,和免疫调节剂,其中靶向集团和免疫调节剂经连接集团连接在一起。
在一个实施方案中,所述靶向集团可特异性地结合肿瘤。
在一个实施方案中,所述靶向集团可特异性地结合肿瘤抗原。所述肿瘤抗原可选自CD19,CD20,CD22,CD33,CD37,CD40,CD52,CD70,或CD79。所述肿瘤抗原也可选自Syndecan-1,Lewis,MUC1,MUC16,PSMA,Cripto,EphA2,EphA3,EphB2,Av integrin,Mesothelin,TAG-72,CAIX,5T4,Folate Receptor 1,BT-062,SLC44A4,Nectin-4,GD2,ED-B,FAP,GPNMB,gpA33,MET,IGF1R,TRAILR1,TRAILR2,RANKL,FAP,或Tenascin。
在一个实施方案中,所述靶向集团是抗体。所述抗体可以是单克隆抗体。所述单克隆抗体可以是人源化,或人源性单克隆抗体。在再一个实施方案中,所述靶向集团选自Rituxan(rituximab,利妥昔单抗),Herceptin(trastuzumab,曲妥珠单抗),或Erbitux(cetuximab,西妥昔单抗)。
在一个实施方案中,所述靶向集团选自a Fab,Fab’,F(ab′)2,single domainantibody,T and Abs dimer,Fv,scFv,dsFv,ds-scFv,Fd,单域抗体(linear antibody),小分子抗体(minibody),双特异抗体(diabody),双特异抗体片断(bispecific antibodyfragment),bibody,tribody,sc-diabody,kappa(lamda)body,BiTE,DVD-Ig,SIP,SMIP,DART,或含有一个或多个CDR的抗体类似物(a small antibody mimetic comprising oneor more CDRs)。
在一个实施方案中,所述靶向集团选自VEGFR的ATWLPPR多肽片段,Thrombospondin-1mimetics,CDCRGDCFCG(cyclic)多肽,SCH 221153片段,NCNGRC(cyclic)多肽,CTTHWGFTLC多肽,CGNKRTRGC多肽(LyP-1),Octreotide,Vapreotide,Lanreotide,C-3940多肽,Decapeptyl,Lupron,Zoladex,或Cetrorelix。
在一个实施方案中,权利要求1的免疫治疗分子,其中所述靶向集团是叶酸或其衍生物。
在一个实施方案中,所述免疫调节剂是免疫激活剂。
在一个实施方案中,所述免疫调节剂是TLR配体。在一个实施方案中,所述免疫调节剂是下列TLR中至少一个的配体:TLR1,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,或TLR9。在再一个实施方案中,权利要求1的免疫治疗分子,其中所述免疫调节剂是TLR7和TLR8的配体。
在一个实施方案中,所述免疫调节剂选自Imiquimod,Resiquimod(R848),IMO2134,IMO205,MGN-1703,MGN-1704,Agatolimod,SD-101,QAX-935,DIMS0150,PollinexQuattro,OM-174,Eritoran,TAK-242,NI-0101,聚肌胞苷酸(Poly I:C),CpG寡聚脱氧核苷酸,或干扰素-b。
在一个实施方案中,所述连接集团选自腙链,多肽链,二硫键链或硫醚键链。
在一个实施方案中,所述连接集团是可被酶切的或非酶切位点的。
本发明还提供一种药物组合物,其包含所述的免疫治疗分子或其药物学可接受的盐以及一种或多种药物学可接受的载体。
在一个实施方案中,所述的药物组合物,还含有第二化学治疗剂。所述的第二化学治疗剂可选自他莫昔芬、雷洛昔芬、阿那曲唑、依西美坦、来曲唑、imatanib、紫杉醇、环磷酰胺、洛伐他汀、minosine、吉西他滨、阿糖胞苷、5-氟尿嘧啶、甲氨喋呤、多西他奇、戈舍瑞林、长春新碱、长春碱、诺考达唑、替尼泊苷、依托泊苷、吉西他滨、epothilone、诺维本、喜树碱、柔红霉素、放线菌素D、米托蒽醌、安吖啶、多柔比星、表柔比星或伊达比星。
本发明还提供一种一种治疗细胞增生性疾病的方法,所述方法包括将治疗有效量的如所述的免疫治疗分子、或其药物学可接受的盐,与药物学可接受的载体一起给药于有此需要的对象,其中所述的细胞增生性疾病得到治疗。
在一个实施方案中,所述的细胞增生性疾病为癌前期病变,或癌症。其中所述的癌症为肺癌、结肠癌、乳腺癌、胰腺癌、前列腺癌、慢性髓细胞性白血病、黑素瘤或卵巢癌。
在一个实施方案中,所述的细胞增生性疾病为乳腺细胞增生性疾病。
在一个实施方案中,所述的乳腺细胞增生性疾病为乳腺癌前期病变。在再一个实施方案中,所述的乳腺癌前期病变选自乳腺非典型增生、原位管癌、和原位小叶癌。
在一个实施方案中,所述的乳腺细胞增生性疾病为乳腺癌。在再一个实施方案中,所述的乳腺癌为雌激素受体阴性乳腺癌。
在一个实施方案中,所述的治疗分子、或其药物学可接受的盐与第二化学治疗剂联合给药。在再一个实施方案中,所述的第二化学治疗药剂选自他莫昔芬、雷洛昔芬、阿那曲唑、依西美坦、来曲唑、imatanib、紫杉醇、环磷酰胺、洛伐他汀、minosine、吉西他滨、阿糖胞苷、5-氟尿嘧啶、甲氨喋呤、多西他奇、戈舍瑞林、长春新碱、长春碱、诺考达唑、替尼泊苷、依托泊苷、吉西他滨、epothilone、诺维本、喜树碱、柔红霉素、放线菌素D、米托蒽醌、安吖啶、多柔比星、表柔比星或伊达比星。
在一个实施方案中,所述的癌症治疗包括肿瘤尺寸的减小。
在一个实施方案中,所述的癌症为转移癌。在再一个实施方案中,所述的癌症治疗包括抑制转移癌细胞的侵袭。
从本文提供的其它描述,包括不同实施例,本发明的其他特征和优点将是显而易见的。所提供的实施例举例说明在实践本发明中有用的不同组分和方法。实施例不限制请求保护的本发明。基于本公开内容,本领域技术人员可以鉴定和采用对于实践本发明有用的其他组分和方法。
附图简述
图1.Balb/c裸鼠注射4x106肿瘤细胞建立癌症模型,每3天鼠尾静脉注射给药一次,对照组(n=10)抗体IgG 5mg/kg,Trastuzumab抗体组(n=10)5mg/kg,R848组(n=10)30ug,Trastuzumab偶联R848抗体组(n=10)5mg/kg,实验为50天测定肿瘤体积为其中观察项目之一。
发明详述
树突细胞是一类在免疫应答与免疫耐受中发挥重要作用的免疫细胞,其最突出的功能特点是在病毒刺激下产生大量的I型干扰素,因此又被称为是天然I型干扰素生产细胞。
树突状细胞是迄今所知的功能最强的抗原提呈细胞。根据其表面分子标记,树突状细胞可以被分成二个亚型,浆细胞样树突细胞(plasmacytoid DC,pDC)和骨髓样树突细胞(myeloid DC,mDC)。通过大量产生I型干扰素、细胞因子、趋化因子以及与其它细胞之间的相互作用等途径,浆细胞样树突细胞广泛地参与到机体的固有免疫和适应性免疫应答过程中,它可以调控NK、T、B等细胞参与免疫反应的强度、持续时间以及应答方式,从而在肿瘤、感染和自身免疫性疾病过程中均发挥十分重要的功能(Liu YJ.IPC:professionaltype 1 interferon-producing cells and plasmacytoid dendritic cellprecursors.Annu Rev Immunol.2005;23:275-306.Gilliet M,Cao W,LiuYJ.Plasmacytoid dendritic cells:sensing nucleic acids in viral infection andautoimmune diseases.Nat Rev Immunol.2008 Aug;8(8):594-606)。
研究发现许多实体肿瘤如乳腺癌和头,颈肿瘤,卵巢癌中有pDC的侵润(TreilleuxI,BlayJY,Bendriss-Vermare N et al.Dendritic cell infiltration and prognosisof early stage breast cancer.Clin Cancer Res 2004;10:7466-7474,Hartmann E,Wollenberg B,Rothenfusser S et al.Identification and functional analysis oftumor-infiltrating plasmacytoid dendritic cells in head and neckcancer.Cancer Res 2003;63:6478-6487.Zou WP,Machelon V,Coulomb-L’Hermin A,etal.Stromal-derived factor-1 in human tumors recruits and alters the functionof plasmacytoid precursor dendritic cells.Nat Med 2001;7:1339-1346)而肿瘤细胞分泌的因子抑制的DC细胞的成熟(Gabrilovich DI,Corak J,Ciernik IF etal.Decreased antigen presentation by dendritic cells in patients with breastcancer.Clin Cancer Res 1997;3:483-490.Bell D,Chomarat P,Broyles D et al.Inbreast carcinoma tissue,immature dendritic cells reside within the tumor,whereas mature dendritic cells are located in peritumoral areas.J Exp Med1999;190:1417-1425.Menetrier-Caux C,Montmain G,Dieu MC et al.Inhibition ofthe differentiation of dendritic cells from CD34(+)progenitors by tumorcells:role of interleukin-6 and macrophage colony-stimulating factor.Blood1998;92:4778-4791)。这些未成熟的DC细胞没能起到调节免疫功能的作用。有证据表明Toll样受体7激动剂Imiquimod,和Toll样受体9激动剂CpG类药物能够刺激肿瘤周边的pDC产生I型IFN进而抑制肿瘤的发展。(Dummer R,Urosevic M,Kempf W et al.Imiquimod inbasal cell carcinoma:how does it work?Br J Dermatol 2003;149:57-58.Miller RL,Gerster JF,Owens ML et al Imiquimod applied topically:a novel immune responsemodifier and new class of drug.Int J Immunopharmacol 1999;21:1-14.Hofmann MA,Kors C,Audring H et al Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastaticmelanoma.J Immunother 2008;31:520-527).
本发明涉及一个用于治疗肿瘤的具有靶向细胞功效以及细胞免疫调节功能的免疫治疗分子,此免疫治疗分子是具有靶向集团-链接分子-调节剂结构的偶联复合物。此免疫治疗分子在体内能达到激活肿瘤免疫和杀伤肿瘤细胞的作用。
本发明提供一种靶向免疫治疗分子,其具有如下结构:靶向集团,连接集团,和免疫调节剂,其中靶向集团和免疫调节剂经连接集团连接在一起。
1.靶向集团
1.1.肿瘤靶点
肿瘤靶点是肿瘤细胞表面相对特异的受体或特定的基因表达蛋白以及相关的配体,可溶性蛋白等。针对该靶标的抗体或其他药物特异性干预调节肿瘤细胞生物学行为的信号通路直接或阻断信号通路来抑制肿瘤细胞生长或促进其凋亡,迄今为止,已有几十余种分子靶点药物被批准用于实体肿瘤或血液系统肿瘤的临床研究及治疗,另有数种分子靶向药物用于血液系统肿瘤。目前非实体肿瘤如血液病肿瘤较常见的靶点为CD19,CD20,CD22,CD30,CD33,CD37,CD40,CD52,CD70,CD79;而在实体肿瘤中Syndecan-1,Lewis,MUC1,EpCAM,Her1,Her2,Her3,MUC16,PSMA,Cripto,EphB2,EphA2,EphA3,Av integrin,Mesothelin,TAG-72,CAIX,5T4,folate receptor 1,BT-062,SLC44A4,Nectin-4,GD2,ED-B,FAP,GPNMB,gpA33,VEGF,VEGFR,MET,IGF1R,TNFR,TRAILR1,TRAILR2,RANKL,FAP,Tenascin。(Scott AM,Wolchok JD,Old LJ.Antibody therapy of cancer.Nat RevCancer.2012 Mar 22;12(4):278-87.)
1.2.治疗性抗体
临床上成功的案例如:Rituxan(Rituximab,利妥昔单抗),是人鼠嵌合抗体,用来治疗B细胞非霍奇金淋巴瘤。它作用在表达于B细胞表面的CD20抗原,90%以上的B细胞非霍奇金淋巴瘤均有表达。Rituxan与CD20结合通过CDC和ADCC引发B细胞溶解,同时也可使药物抵抗性的人体淋巴细胞对一些化疗药的细胞毒性敏感。
Herceptin(Trastuzumab,曲妥珠单抗)是人源化的单抗,作用在人表皮生长因子受体HER2的胞外区域,25%-30%的乳腺癌有表达。Herceptin抗肿瘤作用认为是1)使HER2受体的表达下调,抑制HER2的胞内信号转道通路,诱导细胞凋亡。2)与免疫机制有关,通过依赖抗体的ADCC和CDC杀伤肿瘤细胞。
Erbitux(Cetuximab,西妥昔单抗)是人鼠嵌合抗体,作用在表皮生长因子受体(EGFR)。Erbitux与EGFR结合可抑制其信号转道通路,影响细胞增殖、侵袭转移以及血管生成。抑制EGFR信号转道通路可增强化疗药物和放射治疗的疗效。
Avastin(Bevacizumab,贝伐单抗)是人源化的单抗,其作用靶点是血管皮生长因子(VEGF)。它与VEGF结合抑制VEGFR的信号转导,结果导致抑制肿瘤的新血管生成。
1.3.其它抗体
目前在研发的针对肿瘤靶点的治疗性抗体药物有血液系统疾病肿瘤方面的抗CD19,CD20,CD22,CD33,CD37,CD40,CD52,CD70,CD79单克隆抗体;有用于治疗实体肿瘤的抗Syndecan-1,Lewis,MUC1,MUC16,PSMA,Cripto,EphA2,EphA3,EphB2,Av integrin,Mesothelin,TAG-72,CAIX,5T4,Folate Receptor 1,BT-062,SLC44A4,Nectin-4,GD2,ED-B,FAP,GPNMB,gpA33,MET,IGF1R,TRAILR1,TRAILR2,RANKL,FAP,Tenascin抗体等。(ScottAM,Wolchok JD,Old LJ.Antibody therapy of cancer.Nat Rev Cancer.2012 Mar 22;12(4):278-87)
下表列举了以肿瘤抗原分类的各种正在研发的治疗性抗体:
1.4.抗体片段或变体
下表列举了可用于肿瘤抗原抗体结合的各种抗体形式以及正在研究的肿瘤靶点:
可结合抗原的抗体片断或衍生物:a Fab,Fab’,F(ab′)2,single domainantibody,T and Abs dimer,Fv,scFv,dsFv,ds-scFv,Fd,单域抗体(linear antibody),小分子抗体(minibody),双特异抗体(diabody),双特异抗体片断(bispecific antibodyfragment),bibody,tribody,sc-diabody,kappa(lamda)body,BiTE,DVD-Ig,SIP,SMIP,DART,或含有一个或多个CDR的抗体类似物(a small antibody mimetic comprising oneor more CDRs)。
1.5.其它可特异性结合肿瘤的分子
研究发现许多多肽类分子较特异性的作用在肿瘤血管方面和细胞表面激素受体上。如肿瘤血管方面的有VEGFR的ATWLPPR多肽片段,作用在CD36的Thrombospondin-1mimetics,在Integrins avb 3 and avb 5的ACDCRGDCFCG(cyclic)多肽和SCH 221153片段,作用在Aminopeptidase上的NCNGRC(cyclic)多肽;作用在MMP-2 and MMP-9的CTTHWGFTLC和Lymphatic vessels的CGNKRTRGC多肽(LyP-1);在细胞表面激素受体上有omatostatin receptors的Octreotide,Vapreotide和Lanreotide;Bombesin/GRPreceptor的C-3940多肽,HRH受体的Decapeptyl,Lupron,Zoladex,Cetrorelix。
近年来,Folic acid的研究进展引人注目,叶酸是一种小分子维生素,是细胞分裂所必须的。肿瘤细胞分裂异常,其表面存在着高表达的叶酸受体(FR,Folate receptor)以便捕捉足够的叶酸来支持细胞分裂。
数据表明FR在肿瘤细胞的表达比正常细胞高出20-200倍以上,各种恶性肿瘤FR表达率分别是卵巢癌82%,非小细胞肺癌66%,肾癌64%,结肠癌34%,乳腺癌29%,(Xia W,Low PS.Late-targeted therapies for cancer.J Med Chem.2010;14;53(19):6811-24)且与上皮肿瘤组织的恶性程度及转移侵袭程度呈正相关。FA可以通过细胞表面的FR介导内吞作用将FA吞入胞内,而FA通过其羧基与药物形成FA复合物进入细胞内仍然保持高度亲和力,并在酸性条件下(pH值为5)FR与FA脱离,FA并将药物释放在细胞质内。
临床上可以利用这个传递药物系统来达到选择性攻击肿瘤细胞。叶酸分子量小,无免疫原性,稳定性强,合成价格低廉,重要的是与药物或载体之间的化学键偶联简单易行,以FA为靶向分子构建药物传递系统成为治疗肿瘤的研究热点之一。目前在临床试验阶段的EC145(FA化疗药物偶联复合物)能有效的攻击癌细胞(Pribble P and EdelmanMJ.EC145:a novel targeted agent for adenocarcinoma of the lung.ExpertOpin.Investig.Drugs(2012)21:755-761)。
2.免疫调节剂
2.1.TLR配体
Toll like receptor(Toll样受体,TLR)是树突细胞重要的模式识别受体并在其分化和功能成熟中发挥重要作用,TLR通过识别细菌、虫体、真菌和病毒等保守的病原相关分子模式(PAMP)而捕获病原体,刺激树突细胞分化和功能成熟。
到现在为止,一共有10个人类和13个鼠类TLR家族相继被发现。它们在细胞内均有一定的分布。TLRl、2、4、5、6表达于细胞表面,TLR3、7、8、9存在于细胞的胞内体(endosome)。它们均属I型跨膜蛋白,由胞外区(550-980个氨基酸)、跨膜段和胞内区(约130个氨基酸)3部分组成。胞外区富含亮氨酸重复序列(LRR),能识别病原体成分;胞内区有一个Toll/IL-1R(TIR)区域,是高度保守的蛋白质相互作用区,通过与转接分子的相互作用转导信号,是信号转导的核心元件。
近年来以TLR为靶向药物的研究也有突破性的进展,如通过TLR7MYD88信号途径诱导IFN、IL6和TNF的生成来调节免疫抗病毒、抗肿瘤药物的TLR7/8靶向激动剂Imiquimod和已通过临床二期试验的Resiquimod(R848)(Hemmi H,Kaisho T,Takeuchi O,et al.Smallantiviral compounds activate immune cells via the TLR7 Myd88 dependentsignaling pathway.Nat Immunol,2002;3:196-200;Panter G,Kuznik A,JeralaR.Therapeutic applications of nucleic acids as ligands for Toll likereceptors.Curr Opin Mol Ther,2009;11:133-145.Kronenberger B,Zeuzem S.Currentand future treatment option for HCV,Ann Hepatol,2009;8:103-112).针对TLR9靶点的IMO2134,IMO205,MGN-1703,MGN-1704,CpG-ODN药物Agatolimod,SD-101,QAX-935,DIMS0150等;TLR4也是人们关注的靶点之一现在临床研究药物有单磷酰酯质A成分的Pollinex Quattro,OM-174,Eritoran,TAK-242,NI-0101等等
表中列举了已报道的临床前或临床研究的能通过各种途径激活TLR的分子以及其作用的TLR和临床适应症
在识别核酸的TLR家族成员中,TLR7/8具有很高的相似程度,均可被类似的ssRNA配体活化(Diebold SS,Kaisho T,Hemmi H,et al.Innate antiviral responses bymeans of TLR7 mediated recognition of single stranded RNA.Science.2004;303(5663):1529-1531)。TLR7缺陷型小鼠的研究证实,TLR7和TLR8在病毒识别中起非重,该受体对几个单链RNA病毒的识别是必需的,如甲型流,病毒(influenza A virus)、水泡性口膜炎病毒(vesicular stomatitis virus,VSV)。除此之外TLR7/TLR8还可识别咪唑喹啉/咪喹莫特、咪唑醌醇/R-848、咪唑喹啉/S-27610、洛索立宾、Bropirimine等等。R848是一种小分子的免疫调节剂,它可以通过TLR7-MyD88依赖的信号系统来激活免疫细胞诱导细胞因子的产生,具有活化浆状树突状细胞对靶细胞的细胞毒作用以及刺激树突状细胞产生IFN-和其他免疫刺激分子如CD40,CD80,CD86,OX40-配体,4-1BB-配体,GITR-配体,CD70作用。
通过TLR8可以激活骨髓粒细胞特别是mDC产生IL-12和I型干扰素,而这二种因子又可以化使mDC的功能,使之从免疫耐受/炎症Th2反应到抗肿瘤的Th1以及细胞毒反应。不仅如此,TLR8激活的mDC还可以将坏死的肿瘤细胞处理并提呈给肿瘤特异识别的CD4阳性T细胞和CD8阳性T细胞,TLR8还可以上调I类,II类MHC分子以及共刺激分子如CD80和CD86的表达以增加mDC的激活肿瘤特异性T细胞的能力。TLR7能够激活pDC并在肿瘤微环境中产生大量的I型干扰素和许多免疫刺激分子,这些刺激分子亦可以进一步激活mDC。TLR7激活的pDC还可以通过I型干扰素和共刺激分子如GITR配体来活化NK细胞,激活的NK细胞能够进一步杀伤肿瘤细胞并为树突状细胞产生了大量的坏死的肿瘤细胞,可供树突状细胞提呈抗原之用。
以TLR为靶位,抑制或激活TLR表达或调控TLR信号通路,不仅是炎性疾病新的治疗策略,而且还可作为药物设计和疫苗研制的新靶点。几乎主要用于人类和动物的疫苗佐剂就是利用激发不同PAMP受体以对抗微生物菌或微生物菌衍生物的。基于我们的TLR和树突细胞生物学的理解,用于肿瘤疫苗佐剂治疗癌症的原理就是引导树突细胞像识别病原菌或病毒抗原一样去识别肿瘤抗原。
2.2.其它immune modulators
目前与TLR相同的一系列模式识别受体也被发现如TLR RNA螺旋酶RIG样受体(RLR)和NOD样受体。与TLR不同之处在于RLR路径的活化能够引发I型IFN的表达,而不会形成IL-12和IL-23。目前已知的配体或称为免疫调节剂的有5’triphosphorylated RNA,Short dsRNA 5’triphosphate panhandle-like RNA等。而发现能够调节NOD样受体的免疫调节剂有lipoproteins,PGN,ssRNA,uric acid,ATP,alum,asbestos,flagellin。
3.偶联链接分子(Linkers)
目前常用的偶联链接分子有具有血清中的稳定性和细胞浆内酸性环境中的降解作用的腙链(Hydrazone)(Carter PJ,Senter PD.Antibody-drug conjugates for cancertherapy.Cancer J.2008;14(3):154-69)。具有有被溶酶作用的多肽链(Peptide)(CarterPJ,Senter PD.Antibody-drug conjugates for cancer therapy.Cancer J.2008;14(3):154-69;Sanderson RJ,Hering MA,James SF.In vivo drug-linker stability of ananti-CD30 dipeptide-linked auristatin immunoconjugate.Clin Cancer Res.2005Jan 15;11(2 Pt 1):843-52);以巯基和细胞氧化还原状态进行二硫交换的二硫键链(Disulfde)(Carter PJ,Senter PD.Antibody-drug conjugates for cancertherapy.Cancer J.2008;14(3):154-69.Chaff RV.Targeted cancer therapy:conferring specificity to cytotoxic drugs.Acc Chem Res.2008 Jan;41(1):98-107);还有能够利用胞内蛋白质降解的硫醚键链(Thioether)(Carter PJ,SenterPD.Antibody-drug conjugates for cancer therapy.Cancer J.2008;14(3):154-69.Oflazoglu E,Stone IJ,Gordon K et al.Potent anticarcinoma activity of thehumanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitorauristatin via an uncleavable linker.Clin Cancer Res.2008 Oct 1;14(19):6171-80.)
4.用途
本发明还提供调节肿瘤内的免疫反应的方法。该方法包括步骤:使肿瘤细胞与本发明分子接触,实现肿瘤内的免疫反应的调节。
4.1.治疗用途
本发明的治疗分子可以用于治疗和/或调节细胞异常增殖疾病。在一个实施方案中,本发明可以用作癌症治疗或用于预防癌症。
本文中所使用的“对象”可以是任何一种哺乳动物,例如人、灵长类动物、大鼠、小鼠、狗、猫、牛、马、猪、绵羊、山羊、骆驼。在一个优选的方面,所述对象为人类。
本文中所使用的“有此需要的对象”为患细胞异常增殖疾病的对象,或相对于普通人群,患细胞异常增殖疾病的危险增加的对象。一方面,有此需要的对象有癌前期病症。在优选的方面,有此需要的对象患有癌症。
本文中所使用的术语“细胞异常增殖疾病”是指在这些病变中,细胞不受控的或异常的生长(或二者皆有)可以导致不希望的病变或疾病发生,其中的疾病可以是也可以不是癌症。在一方面,细胞异常增殖疾病包括非癌症病变。
在另一方面,细胞异常增殖疾病包括初期癌或癌前期病变。在另一方面,细胞异常增殖疾病包括癌症。多种要治疗的癌症包括但不限于乳腺癌、肺癌、结肠直肠癌、胰腺癌、卵巢癌、前列腺癌、肾癌、肝癌、脑癌、黑素瘤、多发性骨髓瘤、慢性髓细胞性白血病(chronicmyelogenous leukemia)、血液肿瘤、以及淋巴肿瘤,包括在远离原发肿瘤的其它组织或器官中的转移病灶。要治疗的肿瘤包括但不限于恶性毒瘤、癌瘤、以及腺癌。在一方面,“初期癌细胞”(precancer cell)或“癌前期的细胞”(precancerous cell)为表现出初期癌或癌前期病变的异常增殖的细胞。在另一方面,“癌细胞”或“癌性细胞”为表现出癌症病变的异常增殖的细胞。在一优选方面,癌细胞或癌前期的细胞通过组织样本(例如活组织检查样本)的组织学分类或分级来确定。在另一方面,癌细胞或癌前期的细胞通过采用合适的分子标记物来确定。
本文中所使用的“正常细胞”是指不能被定为“异常增殖”部分的细胞。在一方面,正常细胞缺少失控或异常增长,或两者都缺少。失控和异常增长可以导致不希望的状况或疾病。优选地,正常细胞拥有正常工作的细胞周期关卡控制机制。
本文中所使用的“与细胞接触”是指一种化合物或其它的物质组合物与细胞直接接触,或者接近到足够在细胞内引起希望的生理反应的情况。
本文中所使用的“单一疗法”是指对有此需要的对象给药单一活性化合物或治疗化合物。优选地,单一疗法包括给药在治疗有效量的一种活性化合物。例如,使用本发明的治疗分子、或其药理学上可接受的盐、类似物、或衍生物,对有治疗癌症需要的对象给药。单一疗法和联合治疗相比,后者将多种活性化合物组合给药,优选该组合的每种化合物均为治疗上有效的量。在一优选方面,使用本发明的治疗分子的单一疗法在诱导希望的生理反应上比联合治疗更有效。
本文中所使用的“治疗”说明了为与疾病、病变、失调抗争的目的对病人的处理和照顾,并且包括将本发明的治疗分子给药以预防症状或并发症的发生,减轻症状或并发症,或消除疾病、病变或失调。
在一方面,治疗癌症的结果是肿瘤尺寸的减小。肿瘤尺寸的减小也被称为“肿瘤消退”。在另一方面,治疗癌症的结果是肿瘤体积的减小。另一方面,治疗癌症的结果是肿瘤数量的减少。在另一方面,治疗癌症的结果是在远离原发肿瘤处的其它组织或器官中的转移病灶数量的减少。
在另一方面,治疗癌症的结果是治疗后的对象的人群的平均生存时间与只接受了载体的人群相比有所增加。在另一方面,治疗癌症的结果是治疗后的对象的人群的平均生存时间与未接受治疗的人群相比有所增加。在另一方面,治疗癌症的结果是治疗后的对象的人群的平均生存时间与接受使用非本发明的化合物,或其药理学上可接受的盐、类似物、或衍生物的单一疗法的人群相比有所增加。
在另一方面,治疗癌症的结果是治疗后的对象的人群的死亡率与未接受治疗的人群相比有所下降。在另一方面,治疗癌症的结果是治疗后的对象的人群的与接受使用非本发明的化合物,或其药理学上可接受的盐、类似物、或衍生物的单一疗法的人群相比有所下降。
在另一方面,治疗癌症的结果是肿瘤生长速度降低。在另一方面,治疗或预防细胞增生性疾病的结果是细胞再生长有所降低。在另一优选方面,肿瘤再生长可表现为在治疗停止后肿瘤不再复发。
在另一方面,治疗或预防细胞增生性疾病的结果是细胞增生的速度有所降低。在另一方面,治疗或预防细胞增生性疾病的结果是增生细胞的比例有所降低。
在另一方面,治疗或预防细胞异常增殖的结果是细胞异常增殖范围或区域的尺寸的减小。在另一方面,治疗或预防细胞异常增殖的结果是有异常表现或异常形态的细胞的数量或比例有所下降。
本文中所用的术语“选择性地”的意思是倾向于在某一群体中比在另一群体中以更高的频率发生。在一方面,所对比的群体为细胞群体。在一优选方面,本发明的治疗分子,或其药理学上可接受的盐、类似物、或衍生物选择性地对癌细胞或癌前细胞起作用,而不对正常细胞起作用。优选地,如果事件在群体A中发生的频率大于在群体B中频率的两倍,则相比于群体B中该事件选择性地发生于群体A中。更优选为,如果事件在群体A中发生的频率大于5倍,则该事件选择性地发生;如果事件在群体A中发生的频率大于10倍,则该事件选择性地发生;更优选为,大于50倍;更优选为,大于100倍;最优选为,事件在群体A中发生的频率大于在群体B中频率的1000倍。例如,如果与正常细胞相比,细胞死亡发生在癌细胞中的频率多于两倍,则细胞死亡可以被称为选择性地发生于癌细胞中。
在一方面,提升是指一种物质组合物(例如蛋白质或核酸)所需的生理活性的增长。在一方面,提升可能通过一种物质组合物的浓度增加而发生。
在优选的方面,有效量的本发明的化合物,或其药理学上可接受的盐、类似物、或衍生物对正常细胞没有显著细胞毒性。如果将治疗有效量的一种化合物给药后,不诱导大于10%的正常细胞死亡,则治疗有效量的该化合物对正常细胞没有显著细胞毒性。如果将治疗有效量的一种化合物给药后,不诱导大于10%的正常细胞死亡,则治疗有效量的该化合物不显著影响正常细胞的活力。在另一方面,用凋亡导致细胞死亡。
在其他方面,本发明的治疗分子,或其药物学可接受的盐、类似物、或衍生物可以与第二种化学治疗药物联合给药。该第二种化学治疗药物可以为紫杉烷、芳香酶抑制剂、蒽环类抗生素、靶向微管的药物、拓扑异构酶毒性药、分子靶标或酶的抑制剂(例如,激酶抑制剂)、或胞苷类似物药。在优选的方面,所述化学治疗药物可以是但不限于,他莫昔芬、雷洛昔芬、阿纳托司唑、依西美坦、来曲唑、(imatanib)C、(紫杉醇)、环磷酰胺、洛伐他汀、minosine、阿糖胞苷(araC)、5-氟尿嘧啶(5-FU)、甲氨喋呤(MTX)、泰索帝(紫杉萜)、诺雷德(戈舍瑞林)、长春新碱、长春碱、诺考达唑、替尼泊苷、依托泊苷、健择(吉西他滨)、epothilone、诺维本(navelbine)、喜树碱、柔红霉素(daunonibicin)、放线菌素D、米托蒽醌、安吖啶、多柔比星(阿霉素)、表柔比星、或伊达比星或其它在www.cancer.org中所列的药物。在另一方面,所述第二种化学治疗药物可以是细胞因子,例如G-CSF(粒细胞集落刺激因子)。在另一方面,本发明的治疗分子,或其药理学上可接受的盐、类似物、或衍生物可以与辐射疗法联合给药。在另一方面,本发明的治疗分子,或其药理学上可接受的盐、类似物、或衍生物可以与标准的化学疗法组合联合给药,所述化学疗法组合为例如但不限于,CMF(环磷酰胺、甲氨喋呤和5-氟尿嘧啶)、CAF(环磷酰胺、阿霉素和5-氟尿嘧啶)、AC(阿霉素和环磷酰胺)、FEC(5-氟尿嘧啶、表柔比星和环磷酰胺)、ACT或ATC(阿霉素、环磷酰胺和紫杉醇)、CMFP(环磷酰胺、甲氨喋呤、5-氟尿嘧啶和泼尼松)。
在一方面,本发明的治疗分子,或其药理学上可接受的盐、类似物、或衍生物是以一种合适的剂型给药,该剂型的制备是通过将一种治疗有效量的(例如,足以通过抑制肿瘤生长、杀死肿瘤细胞、治疗或预防细胞异常增殖疾病等实现所需的治疗效果的有效水平)本发明的治疗分子,或其药理学上可接受的盐、类似物、或衍生物,(作为活性成分)与标准的药物载体或稀释剂按照常规步骤(意即,通过制备本发明的药物组合物)结合。
实施例
下文提供了实施例以进一步举例说明本发明的不同特征。这些实施例还举例说明对于实践本发明有用的方法。这些实施例对请求保护的本发明不构成限制。
本发明的申请人进行了大量的实验,采用基因工程技术将Trastuzumab与TLR7/8配体进行了偶联组合,这些偶联组合的药效与Trastuzumab相比具有更高,更强肿瘤杀伤效果。
实施例1
抗HER2人源化抗体Trastuzumab的表达载体构建是根据CAS资料180288-69-1和Carter P等″Humanization of an anti-p185HER2 antibody for human cancertherapy″Proc Natl Acad Sci U S A 1992;89:4285-9公开的抗人HER2单抗资料及序列进行的。抗体Trastuzumab重链可变区基因(Her-2VH)及轻链可变区基因(Her-2VL)是全基因合成(英茂盛业公司)。Trastuzumab抗体重链可变区氨基酸序列为:Glu Val Gin Leu ValGlu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala AlaSer Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly LysGly Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala AspSer Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp GlyGly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val SerSer。TrastuZumab抗体轻链可变区氨基酸序列为:Asp Ile Gln Met Thr Gln Ser Pro SerSer Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln AspVal Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu LeuIle Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser ArgSer Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala ThrTyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys ValGlu Ile Lys
人抗体轻、重链恒定区基因的合成是根据Hieter PA等Cloned human and mousekappa immunoglobulin constant and J region genes conserve homology infunctional segments.Cell.1980;22(1 Pt 1):197-207的文献和Ellison JW等Thenucleotide sequence of a human immunoglobulin C gamma1 gene.Nucleic AcidsRes.1982;10:4071-9的文献从正常人外周血中分离并克隆。恒定区基因的PCR序列引物:重链恒定区HC sense:5‘-GCT AGC ACC AAG GGC CCA TCG GTC TTC C-3’;HC antisense:5‘-TTT ACC GGG AGA CAG GGA GAG GCT CTT C-3’;轻链恒定区LC sense:5‘-ACT GTG GCTGCA CCA TCT GTC TTC ATC T-3’;LC antisense:5‘-ACA CTC TCC CCT GTT GAA GCT CTTTGT G-3’。
采用RT-PCR反应扩增抗体重链和轻链恒定区基因。PCR产物经琼脂糖凝胶电泳純化回收并克隆到pGEM-T载体(Promega公司)中,测序验证后确认获得了正确的克隆。重链恒定区氨基列为:Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser LysSer Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro GluPro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe ProAla Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro SerSer Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn ThrLys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro ProCys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys ProLys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp ValSer His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val HisAsn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val SerVal Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys ValSer Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly GlnPro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys AsnGln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val GluTrp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu AspSer Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr ValAsp Lys Ser Arg Trp GlnGln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr ThrGln Lys Ser Leu Ser Leu Ser Pro Gly Lys。轻链恒定区的氨基酸序列为:Arg Thr ValAla Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly ThrAla Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln TrpLys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln AspSer Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp TyrGlu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro ValThr Lys Ser Phe Asn Arg Gly Glu Cys。
以Her2-VH基因和CH载体为模板通过重叠PCR合成人源化抗体重链基因,反应条件为:95℃15分钟;94℃50秒,58℃50秒,72℃50秒,30个循环;72℃10分钟。并使此PCR的重链基因的5’端含有限制酶位点HindIII和信号肽基因序列,3’端含有翻译终止密码TAA和限制酶位点EcoR I。信号肽基因序列见为:ATG GAT TTT CAG GTG CAG ATT TTC AGC TTC CTGCTAATC AGT GCC TCA GTC ATAATATCC AGA GGA。最后琼脂糖凝胶电泳分离PCR扩增产物,回收目的条带并克隆到pGEM-T载体中,筛选阳性克隆测序。挑选测序正确的克隆用Hind III和EcoR I酶切,经琼脂糖凝胶电泳纯化回收人源化抗体重链片段Her2-VH-CH,与用HindIII和EcoR I酶切的质粒pcDNA3.1(+)(美国Invitrogen公司产品)进行连接,构建成人源化重链真核表达载体pcDNA3.1(+)(Her2-VH-CH)。
以Her2-VL基因和CL载体为模板通过重叠PCR合成人源化抗体轻链基因,反应条件为:95℃15分钟;94℃50秒,58℃50秒,72℃50秒,30个循环;72℃10分钟,得到PCR产物Her2-VL-CL,其5’端含有限制酶位点Hind III和信号肽基因序列,3’端含有翻译终止密码TAA和限制酶位点EcoR I。信号肽基因序列为:ATG GAT TTT CAG GTG CAG ATT TTC AGC TTC CTGCTA ATC AGT GCC TCA GTC ATA ATA TCC AGA GGA与前相同。挑选测序正确的克隆用HindIII和EcoR I酶切,经琼脂糖凝胶电泳纯化回收人源化抗体轻链片段VLCL,与用Hind III和EcoR I酶切的质粒pcDNA3.1载体(Invitrogen公司产品)进行连接,构建成人源化轻链真核表达载体pcDNA3.1(Her2-VL-CL)。
实施例2人源化抗体的稳定表达与纯化
pcDNA3.1(Her2-VL-CL)质粒感染细胞是在组织培养皿中接种3×105CHO-K1细胞(ATCC CRL-9618),细胞培养至90%-95%融合时进行转染。取混合质粒共10μg(pcDNA3.1(+)(Her2-VH-CH)4μg,质粒pcDNA3.1(Her2-VL-CL)6μg)和20μl的Lipofectamine2000(Invitrogen公司产品)分别溶于500μl无血清DMEM培养基,室温静置5分钟,将以上2种液体混合,室温孵育20分钟以使DNA-脂质体复合物形成,其间用3ml无血清的DMEM培养基替换培养皿中的含血清培养基,然后将形成的DNA-脂质体复合物加入到板中,CO2孵箱培养4小时后补加2ml含10%血清的DMEM完全培养基,置于CO2孵箱中继续培养。转染进行24h后细胞换含600μg/ml G418选择培养基筛选高产量抗G418性克隆。筛选得到的高表达克隆用无血清培养基扩大培养,用Protein A亲和柱(GE公司产品)分离纯化抗体,最后以紫外吸收法定量。
实施例3 BIAcore检测抗体亲和力
运用Biacore T100(Biacore AB,GE公司)检测人源化抗体Trastuzumab的亲和力常数。将人源化抗体Trastuzumab通过氨基共价结合与CM5生物传感芯片(GE公司)上,将抗原her2蛋白在PBS/0.05%TWEEN-20去污剂配溶液中配成不同的浓度(2倍比浓度稀释),以50μl/min的流速通过芯片。每次检查之后,用5μl 50mM盐酸水溶液以3μl/min的流速洗涤,从而将残留的抗体从固定化的配体上洗脱下来。用BIAevalution软件(T100 evalution2.0版,GE Healthcare公司),通过非线性回归法分析结合曲线。
实施例4 Trastuzumab-R848偶联的制备
主要试剂:N-羟基琥珀酰亚胺基-3-(2-吡基二硫)-丙酸酯(SPDP)(P3415,美国Sigma公司);二硫苏糖醇(DTT)(233155,Merck公司);超滤离心管Amicon Ultral(UFC901008 15ml,10K,美国Millipore公司);亲和层析柱Ni-NTA Superflow Cartvidge(QIAgen公司);R848(Invivogen公司)。抗体Trastuzumab与R848的偶联样品处理原则具体步骤如下:
制备R848的SPDP衍生物R848-PDP,取适量的R848溶于2ml的0.01mol/L磷酸缓冲液(PBS pH=7.5)中,按n(R848)/n(SPDP)=1/10的投料摩尔比值,计算所需要的SPDP量,先将其溶于无水乙醇中,然后于25℃缓慢将溶于乙醇的SPDP分别搅拌加入含有R848的磷酸缓冲液中,继续缓慢搅拌30min后,离心10000r/min 30s,将R848的SPDP衍生物离心后取上清放入超滤离心管,加入0.02mol/L磷酸缓冲液(含0.15mol/LNacl pH=7.5),3500g,4℃,离心15min,重复三次,以去除剩余的SPDP,即得R848-PDP,浓缩至2ml。用DTT法测定蛋白与SPDP摩尔比,并同时留样做SDS-PAGE电泳。R848-PDP巯基衍生物的制备s是将R848-PDP沉淀分散于上述醋酸盐缓冲液中,加入DTT,使反应体系中DTT的终浓度为50mmol/L,25℃缓慢搅拌30min后用0.02mol/L磷酸缓冲液(含0.15mol/LNacl pH=7.5)离心洗涤3次,以去除DTT并取代醋酸缓冲液,这一步骤得到R848-PDP巯基衍生物R848-SH。二联偶联物Trastuzumab-R848的制备是将Trastuzumab加入DTT使其二硫键断裂,在0.01mol/L的PBS中的R848-SH立即与处理过的Trastuzumab混合,室温反应4小时。
实施例5 Trastuzumab-TLR配体偶联体内肿瘤试验
BALB/c裸鼠40只,8周龄雌雄各半,体质量16至24克。购于上海斯莱克实验动物有限责任公司。动物严格饲养于室温22至26℃,湿度40%-60%的无特定病原体环境下。分别将0.5ml的8x106的BT-474肿瘤细胞接种于8周龄裸小鼠的背部皮下。每隔3d观察记录裸鼠体质量、精神、睡眠、活动、饮食及排便等状况,游标卡尺测量肿瘤长短径,观察成长情况。将40只雌雄各半的BALB/c裸鼠癌症模型随机分为4组,对照抗体组5mg/kg;Trastuzumab抗体组5mg/kg;R84830ug,和Trastuzumab抗体-R848偶联药物组5mg/kg。所有药物均为鼠尾静脉注射给药。每周二次,同样剂量,以肿瘤体积作为治疗指标进行观察,随后每3天观察一次,计算公式按照:肿瘤体积mm3=(长度X宽度2)X0.5。
其他实施方案在下述权利要求内。尽管已显示且描述了几个实施方案,但无需背离本发明的精神和范围即可进行各种修饰。
Claims (36)
1.一种靶向免疫治疗分子,其具有如下结构:靶向集团,连接集团,和免疫调节剂,其中靶向集团和免疫调节剂经连接集团连接在一起。
2.权利要求1的免疫治疗分子,其中所述靶向集团可特异性或优先地结合肿瘤。
3.权利要求1的免疫治疗分子,其中所述靶向集团可特异性或优先地结合肿瘤抗原。
4.权利要求3的免疫治疗分子,其中所述肿瘤抗原选自CD19,CD20,CD22,CD33,CD37,CD40,CD52,CD70,或CD79。
5.权利要求3的免疫治疗分子,其中所述肿瘤抗原选自Syndecan-1,Lewis,MUC1,MUC16,PSMA,Cripto,EphA2,EphA3,EphB2,Avintegrin,Mesothelin,TAG-72,CAIX,5T4,Folate Receptor 1,BT-062,SLC44A4,Nectin-4,GD2,ED-B,FAP,GPNMB,gpA33,MET,IGF1R,TRAILR1,TRAILR2,RANKL,FAP,或Tenascin。
6.权利要求1的免疫治疗分子,其中所述靶向集团是抗体。
7.权利要求1的免疫治疗分子,其中所述靶向集团是单克隆抗体。
8.权利要求1的免疫治疗分子,其中所述靶向集团是人源化,或人源性单克隆抗体。
9.权利要求1的免疫治疗分子,其中所述靶向集团选自Rituxan(rituximab,利妥昔单抗),Herceptin(trastuzumab,曲妥珠单抗),或Erbitux(cetuximab,西妥昔单抗)。
10.权利要求1的免疫治疗分子,其中所述靶向集团选自a Fab,Fab’,F(ab′)2,singledomain antibody,T and Abs dimer,Fv,scFv,dsFv,ds-scFv,Fd,单域抗体(linearantibody),小分子抗体(minibody),双特异抗体(diabody),双特异抗体片断(bispecificantibody fragment),bibody,tribody,sc-diabody,kappa(lamda)body,BiTE,DVD-Ig,SIP,SMIP,DART,或含有一个或多个CDR的抗体类似物。
11.权利要求1的免疫治疗分子,其中所述靶向集团选自VEGFR的ATWLPPR多肽片段,Thrombospondin-1 mimetics,CDCRGDCFCG(cyclic)多肽,SCH 221153片段,NCNGRC(cyclic)多肽,CTTHWGFTLC多肽,CGNKRTRGC多肽(LyP-1),Octreotide,Vapreotide,Lanreotide,C-3940多肽,Decapeptyl,Lupron,Zoladex,或Cetrorelix。
12.权利要求1的免疫治疗分子,其中所述靶向集团是叶酸或其衍生物。
13.权利要求1的免疫治疗分子,其中所述免疫调节剂是免疫激活剂。
14.权利要求1的免疫治疗分子,其中所述免疫调节剂是TLR配体,Nod Lile Receptor配体,RIG-I-Like Receptor配体。。
15.权利要求1的免疫治疗分子,其中所述免疫调节剂是下列TLR中至少一个的配体:TLR1,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,或TLR9。
16.权利要求1的免疫治疗分子,其中所述免疫调节剂是TLR7和TLR8的双配体。
17.权利要求1的免疫治疗分子,其中所述免疫调节剂选自Imiquimod,Resiquimod(R848),IMO2134,IMO205,MGN-1703,MGN-1704,Agatolimod,SD-101,QAX-935,DIMS0150,Pollinex Quattro,OM-174,Eritoran,TAK-242,NI-0101,聚肌胞苷酸(Poly I:C),CpG寡聚脱氧核苷酸,和I型干扰素,IL-12,IL-23,IL-7,IL-15。
18.权利要求1的免疫治疗分子,其中所述连接集团选自腙链,多肽链,二硫键链或硫醚键链。
19.权利要求1的免疫治疗分子,其中所述连接集团是可被酶切的或非酶切位点的。
20.一种药物组合物,其包含权利要求1所述的治疗分子或其药物学可接受的盐以及一种或多种药物学可接受的载体。
21.权利要求20所述的药物组合物,其还含有第二化学治疗剂。
22.权利要求21所述的药物组合物,其中所述的第二化学治疗剂选自他莫昔芬、雷洛昔芬、阿那曲唑、依西美坦、来曲唑、imatanib、紫杉醇、环磷酰胺、洛伐他汀、minosine、吉西他滨、阿糖胞苷、5-氟尿嘧啶、甲氨喋呤、多西他奇、戈舍瑞林、长春新碱、长春碱、诺考达唑、替尼泊苷、依托泊苷、吉西他滨、epothilone、诺维本、喜树碱、柔红霉素、放线菌素D、米托蒽醌、安吖啶、多柔比星、表柔比星或伊达比星。
23.一种治疗细胞异常增殖的方法,所述方法包括将治疗有效量的如权利要求1中所定义的治疗分子、或其药物学可接受的盐,与药物学可接受的载体一起给药于有此需要的对象,其中所述的细胞异常增殖得到有效调节。
24.权利要求23所述的方法,其中所述的细胞异常增殖为癌前期病变。
25.权利要求23所述的方法,其中所述的细胞异常增殖为癌症。
26.权利要求25所述的方法,其中所述的癌症为肺癌、结肠癌、乳腺癌、胰腺癌、前列腺癌、慢性髓细胞性白血病、黑素瘤或卵巢癌,黑素瘤或卵巢癌,皮肤、鼻窦、喉的乳头状瘤,子宫、皮肤、肺、鼻咽、阴茎、喉的乳头状癌。甲状腺、乳腺、胃肠、肺、支气管腺瘤,甲状腺癌、胃癌,肾盂和膀胱的移行上皮癌,皮肤基底细胞癌,皮肤、舌、唇的血管肉瘤,骨肉瘤,颅内的星形细胞瘤和多形胶质母细胞瘤,恶性神经鞘瘤,成神经节细胞瘤,脑膜肉瘤,何杰金氏病,非何杰金氏病,白血病、绒毛上皮癌,恶性葡萄胎,多发骨髓瘤,以及恶性黑色素瘤等。
27.权利要求23所述的方法,其中所述的细胞异常增殖为乳腺细胞增生性疾病。
28.权利要求27所述的方法,其中所述的乳腺细胞异常增殖为乳腺癌前期病变。
29.权利要求28所述的方法,其中所述的乳腺癌前期病变选自乳腺非典型增生、原位管癌、和原位小叶癌。
30.权利要求27所述的方法,其中所述的乳腺细胞增生性疾病为乳腺癌。
31.权利要求30所述的方法,其中所述的乳腺癌为雌激素受体阴性乳腺癌。
32.权利要求23所述的方法,其中所述的治疗分子、或其药物学可接受的盐与第二化学治疗剂联合给药。
33.权利要求32所述的方法,其中所述的第二化学治疗药剂选自他莫昔芬、雷洛昔芬、阿那曲唑、依西美坦、来曲唑、imatanib、紫杉醇、环磷酰胺、洛伐他汀、minosine、吉西他滨、阿糖胞苷、5-氟尿嘧啶、甲氨喋呤、多西他奇、戈舍瑞林、长春新碱、长春碱、诺考达唑、替尼泊苷、依托泊苷、吉西他滨、epothilone、诺维本、喜树碱、柔红霉素、放线菌素D、米托蒽醌、安吖啶、多柔比星、表柔比星或伊达比星。
34.权利要求23所述的方法,其中所述的癌症治疗包括肿瘤尺寸的减小。
35.权利要求25所述的方法,其中所述的癌症为转移癌。
36.权利要求25所述的方法,其中所述的癌症治疗包括抑制转移癌细胞的侵袭。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011353425.2A CN112587658A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011353425.2A CN112587658A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN201210248481.9A CN103566377A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210248481.9A Division CN103566377A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112587658A true CN112587658A (zh) | 2021-04-02 |
Family
ID=49948284
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011353425.2A Pending CN112587658A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN201210248481.9A Pending CN103566377A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN202011353424.8A Pending CN112587671A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN201380033552.6A Pending CN104411329A (zh) | 2012-07-18 | 2013-07-16 | 用于靶向免疫疗法的化合物 |
CN202211286144.9A Pending CN115611988A (zh) | 2012-07-18 | 2013-07-16 | 用于靶向免疫疗法的化合物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210248481.9A Pending CN103566377A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN202011353424.8A Pending CN112587671A (zh) | 2012-07-18 | 2012-07-18 | 癌症的靶向免疫治疗 |
CN201380033552.6A Pending CN104411329A (zh) | 2012-07-18 | 2013-07-16 | 用于靶向免疫疗法的化合物 |
CN202211286144.9A Pending CN115611988A (zh) | 2012-07-18 | 2013-07-16 | 用于靶向免疫疗法的化合物 |
Country Status (18)
Country | Link |
---|---|
US (5) | US9878052B2 (zh) |
EP (1) | EP2874651B1 (zh) |
JP (3) | JP6587936B2 (zh) |
KR (1) | KR20150054768A (zh) |
CN (5) | CN112587658A (zh) |
AR (1) | AR091837A1 (zh) |
AU (1) | AU2013292894A1 (zh) |
BR (1) | BR112015001098A2 (zh) |
CA (1) | CA2878989A1 (zh) |
ES (1) | ES2953395T3 (zh) |
IL (1) | IL236772A0 (zh) |
IN (1) | IN2015DN00385A (zh) |
MX (1) | MX2015000821A (zh) |
RU (1) | RU2015105186A (zh) |
SG (1) | SG11201500399SA (zh) |
TW (1) | TW201408323A (zh) |
WO (1) | WO2014012479A1 (zh) |
ZA (1) | ZA201500318B (zh) |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2639310T3 (es) | 2009-07-02 | 2017-10-26 | Sloan-Kettering Institute For Cancer Research | Nanopartículas fluorescentes basadas en sílice |
BR112012013736A2 (pt) | 2009-12-07 | 2018-08-14 | Univ Leland Stanford Junior | processo para intesificação de terapia com anticorpos antitumor |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
SG10201704611WA (en) * | 2012-12-13 | 2017-07-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
JP6482471B2 (ja) | 2012-12-21 | 2019-03-13 | バイオアライアンス コマンディテール フェンノートシャップ | 親水性の自壊性リンカー及びそのコンジュゲート |
WO2014160183A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
AU2014232907B2 (en) | 2013-03-15 | 2017-12-21 | Cornell University | Multimodal silica-based nanoparticles |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
CN104861063A (zh) * | 2014-01-10 | 2015-08-26 | 博笛生物科技有限公司 | 靶向her2阳性肿瘤的化合物和组合物 |
US10548985B2 (en) * | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
CN104861064A (zh) * | 2014-01-10 | 2015-08-26 | 博笛生物科技有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
CN104861067A (zh) * | 2014-01-10 | 2015-08-26 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
EP3096787A4 (en) * | 2014-01-22 | 2018-02-07 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
US10111963B2 (en) * | 2014-05-29 | 2018-10-30 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
CN106535876B (zh) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 |
EP3157560A4 (en) * | 2014-06-20 | 2018-02-21 | Abgenomics International Inc. | Her2 antibody-drug conjugates |
US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
WO2015200828A1 (en) * | 2014-06-27 | 2015-12-30 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
DK3166976T3 (da) * | 2014-07-09 | 2022-04-11 | Birdie Biopharmaceuticals Inc | Anti-pd-l1-kombinationer til behandling af tumorer |
EP3166973B1 (en) | 2014-07-10 | 2020-02-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
EP3186378A1 (en) * | 2014-08-27 | 2017-07-05 | Peptimed, Inc. | Anti-tumor compositions and methods |
CN112587672A (zh) * | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
CN108148133B (zh) * | 2015-01-06 | 2020-04-24 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
CN108101985B (zh) * | 2015-01-06 | 2020-04-10 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
WO2016167809A1 (en) * | 2015-04-17 | 2016-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Improved t-dm1 therapy |
WO2016183131A1 (en) * | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Ligand ionophore conjugates |
IL293719B2 (en) | 2015-05-21 | 2023-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
EP3302568B1 (en) | 2015-05-29 | 2023-12-06 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
EP3322431A2 (en) | 2015-07-16 | 2018-05-23 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
AU2016304597B2 (en) * | 2015-08-06 | 2022-10-06 | Memorial Sloan Kettering Cancer Center | Methods and compositions for tumor therapy |
AU2016304853C1 (en) * | 2015-08-11 | 2023-03-16 | Orbis Health Solutions Llc | Bacterial and viral vaccine strategy |
EP3344772B1 (en) * | 2015-09-01 | 2020-08-26 | Academia Sinica | Antagonistic pdl1 aptamers and their applications in cancer therapy |
KR20180051651A (ko) | 2015-10-01 | 2018-05-16 | 히트 바이오로직스, 인코퍼레이티드 | 비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법 |
BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
CN115350279A (zh) * | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN115554406A (zh) * | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN106943597A (zh) * | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
AU2017206656B2 (en) * | 2016-01-10 | 2024-02-01 | Neotx Therapeutics Ltd. | Immunopotentiator enhanced superantigen mediated cancer immunotherapy |
KR20180100224A (ko) | 2016-01-11 | 2018-09-07 | 노바르티스 아게 | 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질 |
CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
US10869923B2 (en) * | 2016-03-30 | 2020-12-22 | Microbio Co. Ltd. | Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
AU2017267793B2 (en) | 2016-05-20 | 2024-01-25 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
MX2018014387A (es) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
KR20230142631A (ko) * | 2016-07-01 | 2023-10-11 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 표적 세포 표면 편집을 위한 접합체 |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
CN107574149B (zh) * | 2016-07-05 | 2022-02-18 | 上海细胞治疗研究院 | 一种树突状细胞的促成熟方法及其用途 |
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
CN107773762B (zh) * | 2016-08-31 | 2021-06-15 | 上海干云生物科技有限公司 | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 |
CA3034989A1 (en) * | 2016-09-04 | 2018-03-08 | Targimmune Therapeutics Ag | Chimeric proteins for targeting dsrna to prostate cancer cells |
TW202246349A (zh) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | 抗lag-3抗體及其使用方法 |
EP3533466A4 (en) | 2016-10-28 | 2020-06-10 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION |
US10814036B2 (en) * | 2016-11-07 | 2020-10-27 | Baylor University | Drug-eluting live tissue for transplantation |
CN108084265B (zh) * | 2016-11-23 | 2021-07-02 | 复旦大学 | 特异性结合人的5t4抗原的全人源单域抗体及其应用 |
MX2019006043A (es) | 2016-11-23 | 2019-09-26 | Harpoon Therapeutics Inc | Proteína de unión de antígeno prostático específico de membrana. |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
CN108264561B (zh) * | 2016-12-30 | 2021-09-10 | 惠和生物技术(上海)有限公司 | 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用 |
CN108264558B (zh) * | 2016-12-30 | 2021-01-15 | 上海近岸生物科技有限公司 | 融合抗cd19、抗cd3抗体结构域和t细胞正共刺激分子配体的三特异性分子及应用 |
CN110944672A (zh) * | 2017-01-17 | 2020-03-31 | 得克萨斯A&M大学系统 | 用于改善载物分子向靶细胞的内溶酶体区室递送的内溶酶体靶向偶联物 |
WO2018136725A1 (en) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
EP3585409A4 (en) | 2017-02-27 | 2020-12-02 | Shattuck Labs, Inc. | CHEMERICAL PROTEINS BASED ON CSF1R |
AU2018224852A1 (en) | 2017-02-27 | 2019-07-11 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
EP3585418A4 (en) | 2017-02-27 | 2020-11-25 | Shattuck Labs, Inc. | TIGITE AND LIGHT BASED CHIMERIC PROTEINS |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
WO2018170179A1 (en) | 2017-03-15 | 2018-09-20 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JP7209936B2 (ja) | 2017-05-12 | 2023-01-23 | ハープーン セラピューティクス,インク. | Msln標的三重特異性タンパク質及びその使用方法 |
KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
AU2018271781A1 (en) | 2017-05-25 | 2019-12-12 | Cornell University | Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof |
WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
CA3065929A1 (en) | 2017-06-01 | 2018-12-06 | Michael Wayne SAVILLE | Bispecific antibodies that bind cd123 and cd3 |
BR112019027025A2 (pt) | 2017-06-23 | 2020-06-30 | Birdie Biopharmaceuticals, Inc. | composições farmacêuticas |
WO2019023622A1 (en) * | 2017-07-27 | 2019-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY |
WO2019034868A1 (en) * | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
KR102569133B1 (ko) | 2017-10-13 | 2023-08-21 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
WO2019184909A1 (zh) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
US20210121562A1 (en) | 2018-03-30 | 2021-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
TWI672637B (zh) * | 2018-05-03 | 2019-09-21 | 長庚醫療財團法人林口長庚紀念醫院 | 自體免疫抗體免疫螢光影像型態識別方法 |
KR20210016426A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Cd123 및 cd3에 결합하는 이중특이적 항체의 투약 |
US20210115447A1 (en) * | 2018-06-12 | 2021-04-22 | Oneness Biotech Co., Ltd. | Nucleic acid aptamers targeting lymphocyte activation gene 3 (lag-3) and uses thereof |
WO2020046766A1 (en) * | 2018-08-26 | 2020-03-05 | Oaiscell Biotechnologies | Method for treating glioblastoma |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN114127082A (zh) | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
WO2020256868A1 (en) * | 2019-05-16 | 2020-12-24 | Trustees Of Boston University | Immune system modulators for the treatment of squamous lung premalignancy |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
KR102177776B1 (ko) * | 2019-06-11 | 2020-11-11 | 한국생명공학연구원 | 가디퀴모드를 유효성분으로 포함하는 근력 약화 관련 질환 치료용 조성물 |
CN114269346A (zh) * | 2019-07-08 | 2022-04-01 | 普渡研究基金会 | 用于治疗和预防纤维化疾病状态和癌症的化合物和方法 |
US20220370586A1 (en) * | 2019-08-08 | 2022-11-24 | Cedars-Sinai Medical Center | Method of generating activated t cells for cancer therapy |
WO2021030743A2 (en) * | 2019-08-14 | 2021-02-18 | The Regents Of The University Of California | Smart peptides and transformable nanoparticles for cancer immunotherapy |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
WO2021171264A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosing of a bispecific antibody that binds cd123 and cd3 |
BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
JPWO2021182573A1 (zh) | 2020-03-12 | 2021-09-16 | ||
EP4119160A4 (en) | 2020-03-12 | 2024-04-03 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
US20230139178A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CN111621506B (zh) * | 2020-05-09 | 2021-07-30 | 华中农业大学 | 牛支原体分泌蛋白MbovP0145及其应用 |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
CN111840541A (zh) * | 2020-07-03 | 2020-10-30 | 中山大学 | 聚肌苷酸胞苷酸联合抗cd47抗体在肿瘤治疗中的应用 |
CN111956797B (zh) * | 2020-07-10 | 2022-05-13 | 清华大学 | 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用 |
CN112362640B (zh) * | 2020-10-11 | 2021-10-26 | 华中农业大学 | 一种猪链球菌c-di-AMP合成酶抑制剂的筛选方法及其应用 |
AU2021370647A1 (en) | 2020-10-27 | 2023-06-08 | Elucida Oncology, Inc. | Folate receptor targeted nanoparticle drug conjugates and uses thereof |
CN112957463A (zh) * | 2021-02-22 | 2021-06-15 | 深圳市康居正医药科技有限公司 | 免疫激活型抗体及其应用 |
WO2022226032A1 (en) * | 2021-04-21 | 2022-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Immunostimulatory toll-like receptor agonist-nanoparticle for cancer immunotherapy |
CN117545508A (zh) | 2021-06-23 | 2024-02-09 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
BR112023026992A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
CA3227703A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2023008459A1 (zh) | 2021-07-27 | 2023-02-02 | ||
CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
WO2023014360A1 (en) * | 2021-08-05 | 2023-02-09 | Octagon Therapeutics, Inc. | Treatment and diagnosis of immune disorders relating to aberrant immune cells |
CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
WO2023041982A1 (en) * | 2021-09-17 | 2023-03-23 | Birdie Biopharmaceuticals, Inc. | Combination therapy with deuterated imidazoquinolines |
WO2023070132A1 (en) * | 2021-10-22 | 2023-04-27 | Ohio State Innovation Foundation | Immunotherapies for the treatment of cancer |
WO2023068894A1 (ko) * | 2021-10-22 | 2023-04-27 | 동국대학교 산학협력단 | 자연살해 세포의 면역 항암기능 증진을 위한 표면 개질용 고분자 화합물 |
WO2023076599A1 (en) * | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010132622A2 (en) * | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
CN102170901A (zh) * | 2008-10-01 | 2011-08-31 | 伊玛提克斯生物技术有限公司 | 用于治疗胶质细胞瘤(gbm)和其它癌症的肿瘤相关肽组合物及相关抗癌疫苗 |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US6465189B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Systematic evolution of ligands by exponential enrichment: blended selex |
US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
CA2084987C (en) | 1990-06-11 | 2007-02-13 | Larry Gold | Nucleic acid ligands |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
AU743469C (en) | 1996-08-30 | 2004-02-12 | Rolf Bald | Mirror-symmetrical selection and evolution of nucleic acids |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
DK2283866T3 (en) | 1999-06-25 | 2015-05-18 | Genentech Inc | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES |
US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
DE60140863D1 (de) | 2001-06-10 | 2010-02-04 | Noxxon Pharma Ag | Verwendung von L-Polynukleotiden zur diagnostischen Bilderzeugung |
AU2775402A (en) | 2001-06-29 | 2003-01-02 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
DE60230340D1 (de) | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung |
CN101033242A (zh) | 2001-11-27 | 2007-09-12 | 安那迪斯药品股份有限公司 | 3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用 |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
WO2003105780A2 (en) | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
FI2206517T3 (fi) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
MXPA05007466A (es) | 2003-01-09 | 2006-03-08 | Arizeke Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades pulmonares. |
US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
WO2006113909A2 (en) | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
EP1675614A2 (en) | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US20050239735A1 (en) | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
RU2397171C2 (ru) | 2004-03-26 | 2010-08-20 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | 9-замещенное производное 8-оксоаденина и лекарственное средство |
CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
EP1809671B1 (en) | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
JP2008526765A (ja) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚転移の処置 |
CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
EP1877069A2 (de) | 2005-05-04 | 2008-01-16 | Noxxon Pharma AG | Neue verwendung von spiegelmeren |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
AU2006287416A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
SI2502938T1 (sl) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Protitelesa in imunokonjugati in njihove uporabe |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
PL2125007T3 (pl) * | 2007-02-07 | 2014-07-31 | Univ California | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
JP2011508738A (ja) * | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Cd138発現腫瘍細胞のターゲティングを向上させる方法及び剤 |
MX2010007699A (es) | 2008-01-15 | 2010-08-04 | Meda Ab | Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. |
CA2713137C (en) * | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
WO2009099650A2 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
KR101787309B1 (ko) | 2008-12-09 | 2017-10-18 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
CA2750499A1 (en) * | 2009-01-30 | 2010-08-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
DK2427485T3 (en) * | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | CD133 epitopes |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
BR112013002940A2 (pt) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos |
EP2648719A1 (en) | 2010-12-09 | 2013-10-16 | F.Hoffmann-La Roche Ag | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
AR085633A1 (es) | 2011-03-08 | 2013-10-16 | Baylor Res Inst | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
WO2012143143A1 (en) | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
TW201840336A (zh) * | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
JP6046716B2 (ja) | 2011-08-11 | 2016-12-21 | ハンツマン・アドバンスド・マテリアルズ・アメリカズ・エルエルシー | ベンゾオキサジン化合物の生産方法 |
CN103957939A (zh) | 2011-09-19 | 2014-07-30 | 约翰霍普金斯大学 | 癌症免疫治疗 |
EP2771296B1 (en) * | 2011-10-25 | 2017-09-27 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
SG10201701424QA (en) | 2012-08-23 | 2017-04-27 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
DK3166976T3 (da) | 2014-07-09 | 2022-04-11 | Birdie Biopharmaceuticals Inc | Anti-pd-l1-kombinationer til behandling af tumorer |
CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
BR112019027025A2 (pt) | 2017-06-23 | 2020-06-30 | Birdie Biopharmaceuticals, Inc. | composições farmacêuticas |
-
2012
- 2012-07-18 CN CN202011353425.2A patent/CN112587658A/zh active Pending
- 2012-07-18 CN CN201210248481.9A patent/CN103566377A/zh active Pending
- 2012-07-18 CN CN202011353424.8A patent/CN112587671A/zh active Pending
-
2013
- 2013-07-16 US US14/408,268 patent/US9878052B2/en active Active
- 2013-07-16 CA CA2878989A patent/CA2878989A1/en not_active Abandoned
- 2013-07-16 EP EP13820359.1A patent/EP2874651B1/en active Active
- 2013-07-16 ES ES13820359T patent/ES2953395T3/es active Active
- 2013-07-16 WO PCT/CN2013/079441 patent/WO2014012479A1/en active Application Filing
- 2013-07-16 MX MX2015000821A patent/MX2015000821A/es unknown
- 2013-07-16 KR KR1020157003785A patent/KR20150054768A/ko not_active Application Discontinuation
- 2013-07-16 RU RU2015105186A patent/RU2015105186A/ru not_active Application Discontinuation
- 2013-07-16 CN CN201380033552.6A patent/CN104411329A/zh active Pending
- 2013-07-16 JP JP2015521961A patent/JP6587936B2/ja active Active
- 2013-07-16 BR BR112015001098A patent/BR112015001098A2/pt not_active IP Right Cessation
- 2013-07-16 AU AU2013292894A patent/AU2013292894A1/en not_active Abandoned
- 2013-07-16 SG SG11201500399SA patent/SG11201500399SA/en unknown
- 2013-07-16 CN CN202211286144.9A patent/CN115611988A/zh active Pending
- 2013-07-17 TW TW102125608A patent/TW201408323A/zh unknown
- 2013-07-18 AR ARP130102565A patent/AR091837A1/es unknown
-
2015
- 2015-01-15 IN IN385DEN2015 patent/IN2015DN00385A/en unknown
- 2015-01-16 ZA ZA2015/00318A patent/ZA201500318B/en unknown
- 2015-01-18 IL IL236772A patent/IL236772A0/en unknown
-
2017
- 2017-12-20 US US15/849,436 patent/US10548988B2/en active Active
- 2017-12-20 US US15/849,470 patent/US10660971B2/en active Active
-
2019
- 2019-09-11 JP JP2019165174A patent/JP7062298B2/ja active Active
-
2020
- 2020-02-18 US US16/794,056 patent/US20200246478A1/en not_active Abandoned
- 2020-02-18 US US16/794,069 patent/US20200179527A1/en not_active Abandoned
-
2022
- 2022-04-13 JP JP2022066294A patent/JP2022092041A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102170901A (zh) * | 2008-10-01 | 2011-08-31 | 伊玛提克斯生物技术有限公司 | 用于治疗胶质细胞瘤(gbm)和其它癌症的肿瘤相关肽组合物及相关抗癌疫苗 |
WO2010132622A2 (en) * | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112587658A (zh) | 癌症的靶向免疫治疗 | |
US20210024646A1 (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
CN108101825B (zh) | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 | |
CN107530422B (zh) | Cd48抗体和其缀合物 | |
KR20180021723A (ko) | 항체-약물 콘주게이트의 선택적 제조 방법 | |
TW201116300A (en) | DR5 Ligand Drug Conjugates | |
US20230173093A1 (en) | Charge variant linkers | |
JP2022105640A (ja) | 四級化チューブリシン化合物の複合体 | |
AU2017389094B2 (en) | Aptamer-drug conjugate and use thereof | |
CN110770256A (zh) | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 | |
KR20200135841A (ko) | 고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도 | |
CN116528911A (zh) | 抗cd73抗体、抗体偶联药物及其用途 | |
US20200188525A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
CN110831622B (zh) | Fgl2单克隆抗体及其在治疗恶性肿瘤中的用途 | |
US20220362394A1 (en) | Anti-bcma antibody conjugates | |
WO2022048521A1 (zh) | 抗c-Met抗体药物偶联物及其应用 | |
US20220047716A1 (en) | Combination therapies with anti-folate receptor antibody conjugates | |
US20200297863A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
RU2814164C2 (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
WO2023124963A1 (zh) | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 | |
US20230272109A1 (en) | Anti-claudin 18.2 antibody and antibody-drug conjugate thereof | |
US20240115712A1 (en) | Semicarbazone-based saponin conjugate | |
CN115991775A (zh) | 抗cxcr4单域抗体、双特异性抗体及药物偶联物 | |
WO2022235971A9 (en) | Compositions for inhibiting growth of targeted cells | |
CN116059392A (zh) | 配体偶联物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |